Immunic AG ist ein junges Biotech-Unternehmen mit Sitz in der Münchner Biotech-Drehscheibe Martinsried und Halle/Saale, die Arzneimittel im Immunologieraum entwickelt, insbesondere für Autoimmunkrankheiten oder Erkrankungen, die in ihrer Pathogenese eine wichtige Immunologiekomponente aufweisen.
Investors 5
| Date | Name | Website |
| - | bmp Ventur... | bmp.com |
| - | Omega Fund... | omegafunds... |
| - | Fund+ | fundplus.b... |
| - | Life Scien... | lspvc.com |
| - | Pontifax V... | pontifax.c... |
Mentions in press and media 19
| Date | Title | Description | Source |
| 06.08.2021 | Immunic, Inc. Reports Second Quarter 2021 Financial Results ... | NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceu... | prnewswire... |
| 15.07.2021 | Immunic, Inc. Announces Pricing of $45 Million Public Offeri... | NEW YORK, July 15, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a ... | prnewswire... |
| 14.07.2021 | Immunic, Inc. Announces Proposed Public Offering of Common S... | NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a ... | prnewswire... |
| 01.07.2021 | Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase... | NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceu... | prnewswire... |
| 15.04.2021 | Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg C... | NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmac... | prnewswire... |
| 26.02.2021 | Immunic, Inc. Reports Year End 2020 Financial Results and Hi... | NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmace... | prnewswire... |
| 18.02.2021 | Immunic, Inc. Announces Positive Top-Line Data From Investig... | NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmace... | prnewswire... |
| 17.02.2021 | Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Ev... | NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmace... | prnewswire... |
| 17.11.2020 | Immunic, Inc. Announces Formation of Scientific-Medical Advi... | NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmace... | prnewswire... |
| 05.11.2020 | Immunic, Inc. Reports Third Quarter 2020 Financial Results a... | NEW YORK, Nov. 5, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceu... | prnewswire... |
Show more